GENE therapy company Oxford Biomedica expects five clinical trials to be under way by the end of this year.
The firm, an Oxford University spin-out based at Oxford Science Park, said work on its new £2.2m laboratory in Cowley, was on track to open in the first half of 2012.
Treatment of all six patients in a trial of its experimental Parkinson's Disease therapy, ProSavin, has been completed and Biomedica said it would review all patients treated with the drug next month.
Its gene-based therapies for eye disease were also progressing, said the company, which has a net cash balance of £17.5m.
Chief executive John Dawson said: "Developing pioneering gene therapy programmes demands a significant amount of research and development, regulatory, manufacturing and commercial expertise and, with five clinical programmes expected to be underway by the end of 2011, we are pleased with our achievements this year.
"With clear strategic priorities ahead, all efforts remain focused on leveraging the potential of our novel technology platforms."
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules here